1. Home
  2. UNTY vs LYEL Comparison

UNTY vs LYEL Comparison

Compare UNTY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unity Bancorp Inc.

UNTY

Unity Bancorp Inc.

HOLD

Current Price

$51.75

Market Cap

497.6M

Sector

Finance

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$19.96

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UNTY
LYEL
Founded
1991
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
497.6M
556.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
UNTY
LYEL
Price
$51.75
$19.96
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$65.00
$30.60
AVG Volume (30 Days)
42.6K
75.8K
Earning Date
04-14-2026
05-13-2026
Dividend Yield
1.23%
N/A
EPS Growth
39.66
N/A
EPS
5.67
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$12.14
N/A
Revenue Next Year
$9.56
$8,712.13
P/E Ratio
$9.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.67
$0.39
52 Week High
$57.30
$45.00

Technical Indicators

Market Signals
Indicator
UNTY
LYEL
Relative Strength Index (RSI) 46.34 38.23
Support Level $50.54 $16.20
Resistance Level $53.61 $26.89
Average True Range (ATR) 1.57 1.61
MACD -0.27 -0.41
Stochastic Oscillator 28.36 4.51

Price Performance

Historical Comparison
UNTY
LYEL

About UNTY Unity Bancorp Inc.

Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. The Company has elected to become a financial holding company pursuant to regulations of the Board of Governors of the Federal Reserve System (the FRB). The Company's primary business is ownership and supervision of the Bank. The Company and the Bank derive a majority of their revenue from net interest income (i.e., the difference between the interest received on loans and securities and the interest paid on deposits and borrowings). The Company, through the Bank, conducts a traditional and community-oriented commercial banking business and services, personal and business checking accounts, time deposits, money market accounts, savings accounts, credit cards, automated teller service, and others.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: